Linearis
Linearis Ventures, founded in 2023 and based in Montreal, Quebec, focuses on advancing healthcare through strategic investments in innovative life sciences companies. The firm is dedicated to enhancing disease prevention, detection, and treatment by leveraging expertise in biomarker discovery and drug development. Linearis is distinguished by its collaboration with leading experts, including Dr. Yoshua Bengio, a prominent figure in artificial intelligence, and Dr. David Wishart, known for his work on the Human Metabolome Database. The company's approach integrates AI-driven methodologies to develop disease signatures that reveal causal relationships within human omics and various diseases. By emphasizing non-invasive and accessible diagnostic techniques, Linearis aims to transform healthcare systems and improve patient outcomes, particularly in areas such as cancer, diabetes, infectious diseases, and chronic conditions.
Top Regions
Top Stages
3 past transactions
Feldan Therapeutics
Venture Round in 2025
Feldan Therapeutics is a biopharmaceutical company focused on developing innovative therapies using its patented Feldan Shuttle technology. This platform facilitates rapid and secure intracellular delivery of therapeutics, expanding treatment possibilities by accessing previously unreachable cellular components. The company's current pipeline comprises clinical programs leveraging this unique technology to advance novel therapeutic applications.
Noetik
Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.
Zilia
Zilia is a medical technology company that has developed a non-invasive platform using imaging, spectrometry, and artificial intelligence to quantitatively measure biomarkers in the human eye. Its initial product, Zilia Ocular, is a retinal camera designed to quantify oxygen saturation, a critical biomarker for ocular diseases like glaucoma, diabetic retinopathy, and age-related macular degeneration. The company aims to transform the prevention, diagnosis, and management of these diseases by providing actionable data on the eye's metabolic activity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.